In a filing, Mirum Pharmaceuticals Inc revealed its CHIEF FINANCIAL OFFICER BJERKHOLT ERIC acquired Company’s shares for reported $49600.0 on Mar 27 ’24. In the deal valued at $24.80 per share,2,000 shares were bought. As a result of this transaction, BJERKHOLT ERIC now holds 14,000 shares worth roughly $0.34 million.
Then, Radovich Peter sold 4,303 shares, generating $111,017 in total proceeds. Upon selling the shares at $25.80, the PRESIDENT AND COO now owns 29,013 shares.
Before that, BJERKHOLT ERIC bought 2,000 shares. Mirum Pharmaceuticals Inc shares valued at $51,600 were divested by the CHIEF FINANCIAL OFFICER at a price of $25.80 per share. As a result of the transaction, BJERKHOLT ERIC now holds 12,000 shares, worth roughly $0.29 million.
Stifel initiated its Mirum Pharmaceuticals Inc [MIRM] rating to a Buy in a research note published on April 17, 2024; the price target was $48. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid December has reiterated a ‘”a Buy”‘ rating for it. Morgan Stanley started covering the stock on November 13, 2023. It rated MIRM as “an Overweight”.
Price Performance Review of MIRM
On Tuesday, Mirum Pharmaceuticals Inc [NASDAQ:MIRM] saw its stock jump 1.03% to $24.42. Over the last five days, the stock has gained 1.71%. Mirum Pharmaceuticals Inc shares have fallen nearly -17.28% since the year began. Nevertheless, the stocks have fallen -10.42% over the past one year. While a 52-week high of $35.56 was reached on 01/03/24, a 52-week low of $23.29 was recorded on 04/18/24. SMA at 50 days reached $26.77, while 200 days put it at $28.14. A total of 0.42 million shares were traded, compared to the trading of 0.25 million shares in the previous session.
Levels Of Support And Resistance For MIRM Stock
The 24-hour chart illustrates a support level at 24.14, which if violated will result in even more drops to 23.87. On the upside, there is a resistance level at 24.85. A further resistance level may holdings at 25.29. The Relative Strength Index (RSI) on the 14-day chart is 42.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.69, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.96%. Stochastics %K at 25.40% indicates the stock is a holding.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $50 price target.
